A case of Pott's disease with epidural abscess and probable cerebral tuberculoma following Bacillus Calmette-Guérin therapy for superficial bladder cancer

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 21, Issue 1, 2010, Pages

  Josephson, Colin B ^a   Al Azri, Saleh ^a   Smyth, Daniel J ^a   Haase, David ^a   Johnston, B Lynn ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

IFN 2b; Intravesical BCG; Pott's tuberculoma

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; CEFAZOLIN; DEXAMETHASONE; ETHAMBUTOL; ISONIAZID; PIPERACILLIN PLUS TAZOBACTAM; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN;

AGED; ARTICLE; BLADDER CANCER; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYSTOSCOPY; DISKITIS; DRUG SUBSTITUTION; EPIDURAL ABSCESS; HUMAN; INTRACRANIAL TUBERCULOMA; KIDNEY CYST; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; PSOAS ABSCESS; TRANSURETHRAL RESECTION; TUBERCULOUS SPONDYLITIS; ULTRASOUND; X RAY;

EID: 77950831044     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2010/572410     Document Type: Article

References (36)

1. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976;116:180-183
2. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology 2005;66:4-34.
3. Lamm D, Herr H, Jakse G, et al. Updated concepts and treatment of carcinoma in situ. Urol Oncol 1998; 4:130-138
4. Joudi FN, Smith BJ, O'Donnell MA, National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006;24:344-348
5. O'Donnell MA, Lilli K, Leopold C, National Bacillus Calmette- Guérin/Interferon Phase 2 Investigator Group. Interim results from a national multicenter phase II trial of combination bacillus Calmette- Guérin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004;172:888-893
6. Lamm DL. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000;31(Suppl 3):S86-90.
7. Gonzalez OY, Musher DM, Brar I, et al. Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003;36:140-148
8. Niemann S, Harmsen D, Rusch-Gerdes S, Richter E. Differentiation of clinical Mycobacterium tuberculosis complex isolates by gyrB DNA sequence polymorphism analysis. J Clin Microbiol 2000;38:3231-3234
9. Prescott S, Jackson AM, Hawkyard SJ, Alexandroff AB, James K. Mechanisms of action of intravesical bacille Calmette-Guérin: Local immune mechanisms. Clin Infect Dis 2000;31(Suppl 3):S91-3.
10. Wittes RC. Immunology of bacille Calmette-Guérin and related topics. Clin Infect Dis 2000;31(Suppl 3):S59-63.
11. Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
12. Abu-Nader R, Terrell CL. Mycobacterium bovis vertebral osteomyelitis as a complication of intravesical BCG use. Mayo Clin Proc 2002;77:393-397
13. Aljada IS, Crane JK, Corriere N, Wagle DG, Amsterdam D. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol 1999;37:2106-2108
14. Fishman JR, Walton DT, Flynn NM, Benson DR, deVere White RW. Tuberculous spondylitis as a complication of intravesical bacillus Calmette-Guérin therapy. J Urol 1993;149:584-587
15. Katz DS, Wogalter H, D'Esposito RF, Cunha BA. Mycobacterium bovis vertebral osteomyelitis and psoas abscess after intravesical BCG therapy for bladder carcinoma. Urology 1992;40:63-66
16. Morgan MB, Iseman MD. Mycobacterium bovis vertebral osteomyelitis as a complication of intravesical administration of bacille Calmette-Guérin. Am J Med 1996;100:372-373
17. Nikaido T, Ishibashi K, Otani K, et al. Mycobacterium bovis BCG vertebral osteomyelitis after intravesical BCG therapy, diagnosed by PCR-based genomic deletion analysis. J Clin Microbiol 2007;45:4085-4087
18. Rozenblit A, Wasserman E, Marin ML, Veith FJ, Cynamon J, Rozenblit G. Infected aortic aneurysm and vertebral osteomyelitis after intravesical bacillus Calmette-Guérin therapy. AJR Am J Roentgenol 1996;167:711-713
19. Sugita Y, Chokyu H, Gotoh A, et al. Tuberculous spondylitis after intravesical BCG instillation: A case report. Nippon Hinyokika Gakkai Zasshi 1995;86:1493-1496
20. Mavrogenis AF, Sakellariou VI, Tsiodras S, Papagelopoulos PJ. Late Mycobacterium bovis spondylitis after intravesical BCG therapy. Joint Bone Spine 2009;76:296-300.
21. Luo Y, Chen X, Downs TM, Dewolf WC, O'Donnell MA. IFN-α enhances TH1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis Calmette-Guérin immunotherapy. J Immunol 1999;162:2399-2405
22. Van der Meijden. Practical approaches to the prevention and treatment of adverse reactions to BCG. Eur Urol 1995;27(Suppl 1):23-28
23. Steg A, Leleu C, Debre B, Boccon-Gibod L, Sicard D. Systemic bacillus Calmette-Guerin infection, 'BCGitis', in patients treated by intravesical bascillus Calmette-Guerin therapy for bladder cancer. Eur Urol 1989;16:161-164
24. Civen R, Berlin G, Panosian C. Vertebral osteomyelitis after intravesical administration of Bacille Calmette-Guerin. Clin Infect Dis 1994;18:1013-1014
25. Hakim S, Heaney JA, Heinz T, Zwolak RW. Psoas abscess following intravesical bacillus Calmette-Guerin for bladder cancer: A case report. J Urol 1993;150:188-189
26. Palayew M, Briedis D, Libman M, Michel RP, Levy RD. Disseminated infection after intravesical BCG immunotherapy. Detection of organisms in pulmonary tissue. Chest 1993;104:307-309
27. Lamm DL. Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 1992;19:565-572
28. Yossepowitch O, Eggener SE, Bochner BH, Donat SM, Herr HW, Dalbagni G. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. J Urol 2006;176:482-485
29. Bowyer L, Hall RR, Reading J, Marsh MM. The persistence of bacilli Calmette-Guerin in the bladder after intravesical treatment for bladder cancer. Br J Urol 1995;752:188-192
30. Floyd MM, Silcox VA, Jones WD Jr, Butler WR, Kilburn JO. Separation of Mycobacterium bovis BCG from Mycobacterium tuberculosis and Mycobacterium bovis by using high-performance liquid chromatography of mycolic acids. J Clin Microbiol 1992;30:1327-1330
31. van Soolingen D, Hermans PW, de Haas PE, van Embden JD. Insertion element IS1081-associated restriction fragment length polymorphisms in Mycobacterium tuberculosis complex species: A reliable tool for recognizing Mycobacterium bovis BCG. J Clin Microbiol 1992;30:1772-1777
32. Jones WD Jr. Differentiation of known strains of BCG from isolates of Mycobacterium bovis and Mycobacterium tuberculosis by using mycobacteriophage 33D. J Clin Microbiol 1975;1:391-392
33. Hermans PW, van Soolingen D, van Embden JD. Characterization of a major polymorphic tandem repeat in Mycobacterium tuberculosis and its potential use in the epidemiology of Mycobacterium kansasii and Mycobacterium gordonae. J Bacteriol 1992;147:4157-4165
34. World Health Organization. Treatment of tuberculosis: Guidelines for national programmes. In: WHO Report 2003. Geneva: World Health Organization, 2003.
35. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008;(1):CD002244.
36. Repchinsky C, ed. Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Health Professionals. Canadian Pharmacists Association, 2009:1629-1630